AngioDynamics, Inc. (NASDAQ: ANGO) Q2 2026 Earnings Overview

Core Insights - AngioDynamics reported a Q2 2026 EPS of -$0.15, missing the estimated -$0.10, but exceeded revenue expectations with $79.43 million compared to the estimated $76.7 million [1][6] - The company experienced double-digit growth in its medical technology segment, contributing to increased profitability despite a negative P/E ratio of approximately -14.67 [2][6] - AngioDynamics raised its fiscal year 2026 adjusted EPS guidance, indicating a positive outlook for future performance, although shares declined by 1.8% to close at $12.87 [4][6] Financial Performance - Analysts had forecasted a quarterly loss of 10 cents per share, which is deeper than the 4 cents per share loss from the same quarter last year [3] - Revenue of $79.43 million surpassed the previous year's $72.84 million, indicating a positive trend in sales [3] - The company's price-to-sales ratio of about 1.56 suggests that investors are paying $1.56 for every dollar of sales, reflecting confidence in its revenue-generating capabilities [3] Analyst Sentiment - Canaccord Genuity analyst William Plovanic maintained a Buy rating and increased the price target from $17 to $18, indicating positive sentiment from analysts regarding the company's potential [4] - Despite financial challenges, the company maintains a strong current ratio of about 2.29, suggesting solid ability to cover short-term liabilities with short-term assets [5]